证券代码：002007 证券简称：华兰生物 公告编号：2025-044 经总经理提名，聘任李萍女士为公司财务总监，简历详见附件。李萍女士的 任职资格已经董事会审计委员会和提名委员会审核通过，符合相关法律法规规定 的任职条件，任期自本次董事会审议通过之日起至第九届董事会届满之日止。 特此公告。 华兰生物工程股份有限公司董事会 华兰生物工程股份有限公司 关于财务总监辞职暨聘任财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、财务总监辞职情况 华兰生物工程股份有限公司（以下简称"公司"）董事会于近日收到公司财 务总监谢军民先生的辞职报告，谢军民先生因工作调动原因申请辞去公司财务总 监，辞职后谢军民先生将会继续担任参股公司其他职务，其辞职报告自送达公司 董事会之日起生效。谢军民先生原定任期至公司第九届董事会任期届满时止。截 至本公告披露日，谢军民先生持有公司股份 1,313,380 股，辞职后其所持股份将 按照《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等相关 规定进行管理。 谢军民先生在担任公司财务总监期间，勤勉尽责、恪尽职守，公司 ...

华兰生物工程股份有限公司 独立董事提名人声明 提名人华兰生物工程股份有限公司董事会现就提名张志谦为华兰生物工 程股份有限公司第 9 届董事会独立董事候选人发表公开声明。被提名人已书面同 意作为华兰生物工程股份有限公司第 9 届董事会独立董事候选人（参见该独立董事 候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、 全部兼职、有无重大失信等不 良记录等情况后作出的，本提名人认为被提名人符合 相关法律、行政法规、部门规章、规范性文件和深圳证券交易所 业务规则对独立董 事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过华兰生物工程股份有限公司第 9 届董事会提名委员 会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他 可能影响独立履职情形的密切关系。 √是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所业务规则规定的独立董事任职资格和条件。 √是 □ 否 四、被提名人符合公司章程规定的独立董事任职条件。 √ ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-041 华兰生物工程股份有限公司 关于独立董事辞职暨补选第九届董事会 独立董事并调整董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于独立董事辞职的情况说明 华兰生物工程股份有限公司（以下简称"公司"）董事会于近日收到公司独 立董事王云龙先生提交的书面辞职报告。王云龙先生因个人原因申请辞去公司独 立董事、提名委员会、审计委员会委员职务。根据相关法律法规，王云龙先生的 辞职报告将在公司股东会选举产生新任独立董事后生效。 公司独立董事王云龙先生的辞职生效后，其在第九届董事会各专门委员会中 的空缺（第九届董事会提名委员会、审计委员会委员职务）将由张志谦先生接替， 鉴于张志谦先生目前为公司独立董事候选人，尚未当选独立董事，故该事项尚需 经股东会审议通过《关于补选第九届董事会独立董事的议案》方可生效，委员任 期自股东会审议通过之日起至第九届董事会届满之日止。 调整生效后公司第九届董事会各专门委员会的人员构成如下： | 专门委员会名称 | 成员 | 召集人（主任委员） | | ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-045 华兰生物工程股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 （1）截止 2025 年 11 月 10 日下午收市时，在中国证券登记结算有限责任公司深圳分公司登记在册的本 公司全体股东有权出席股东会，并可以书面形式委托代理人出席会议和参加表决，该股东代理人不必是 本公司股东，或在网络投票时间内参加网络投票。 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 17 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 17 日 9:15-9:25，9:30 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-039 华兰生物工程股份有限公司 关于第九届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华兰生物工程股份有限公司（以下简称"公司"）第九届董事会第三次会议 于 2025 年 10 月 17 日以电话或电子邮件方式发出通知，于 2025 年 10 月 29 日在 公司三楼办公室以通讯表决的方式召开。会议由公司董事长安康先生主持。会议 应到董事 9 名，实到董事 9 名。会议符合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 王云龙先生因个人原因申请辞去公司独立董事、提名委员会委员、审计委员 会委员职务，辞去上述职务后，王云龙先生不在公司担任任何职务。王云龙先生 的原定任期至公司第九届董事会任期届满之日止，王云龙先生的辞职报告将在公 司股东会选举产生新任独立董事后生效。 经公司提名委员会及董事会审核，公司董事会同意补选张志谦先生为公司第 九届董事会独立董事，任期自股东会审议通过之日起至第九届董事会任期 ...

Group 1 - The core viewpoint of the article highlights that Hualan Biological's third-quarter revenue decreased by 14.00% to 1.581 billion yuan, while net profit fell by 44.45% to 269 million yuan [1] - For the first three quarters, the company's revenue was 3.379 billion yuan, representing a decline of 3.20%, and net profit was 784 million yuan, down 15.07% [1]

Financial Performance - The company's revenue for Q3 2025 was CNY 1,580,688,450.84, representing a decrease of 14.00% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 268,563,529.57, down 44.45% year-on-year[5] - Basic earnings per share decreased by 44.64% to CNY 0.1467[5] - Total operating revenue for the current period is ¥3,378,886,377.05, a decrease of 3.2% from ¥3,490,648,261.92 in the previous period[18] - Net profit for the current period is ¥827,700,992.33, down 18.1% from ¥1,011,158,954.78 in the previous period[19] - Basic earnings per share for the current period is ¥0.4291, down from ¥0.5056 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 16,267,369,607.56, a slight decrease of 0.26% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to CNY 16,267,369,607.56, a slight decrease from CNY 16,309,951,355.29 at the beginning of the period[15] - Current assets increased to CNY 10,048,714,890.01 from CNY 9,616,191,068.19, reflecting a growth of approximately 4.5%[15] - Total liabilities increased to CNY 3,017,772,127.88 from CNY 2,463,225,371.87, marking an increase of about 22.5%[16] - The company's equity decreased to CNY 13,249,597,479.68 from CNY 13,846,725,983.42, reflecting a decline of approximately 4.3%[16] Cash Flow - Cash flow from investment activities increased by 3871.86% year-on-year, mainly due to a decrease in cash paid for investments[11] - The net cash flow from operating activities is ¥450,628,814.59, slightly down from ¥459,709,426.55 in the previous period[20] - Cash inflow from investment activities decreased to ¥9,673,231,639.89 from ¥18,045,530,207.37 in the previous period[20] - Cash outflow for investment activities was ¥8,936,858,346.82, compared to ¥18,026,990,442.39 in the previous period[20] - Net cash flow from financing activities was -859,196,666.44, compared to -627,795,396.80 in the previous period, indicating a decline in financing activities[21] - The cash and cash equivalents at the end of the period reached 1,686,241,001.06, an increase from 839,732,455.35 at the end of the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 147,902[10] - Cash dividends and interest payments totaled 390,198,653.05, showing the company's commitment to returning value to shareholders[21] Expenses and Financial Ratios - The company's weighted average return on equity was 2.25%, down 1.91% from the previous year[5] - The company experienced a 91.35% increase in financial expenses compared to the same period last year, attributed to reduced interest income[11] - Other income decreased by 55.07% year-on-year, primarily due to a reduction in government subsidies received[11] - The company reported a decrease in research and development expenses to ¥234,642,551.42 from ¥211,913,321.30 in the previous period, indicating a focus on innovation[18] Debt and Obligations - The company reported a 50.32% reduction in short-term borrowings compared to the beginning of the year, primarily due to repayment of maturing credit loans[11] - Short-term borrowings decreased significantly to CNY 447,000,000.00 from CNY 899,730,000.00, a reduction of about 50.3%[16] - The company incurred 1,179,380,000.00 in cash payments for debt repayment, indicating significant debt obligations[21] Accounting and Reporting - The company did not undergo an audit for the third quarter financial report, which may affect the perception of financial reliability[22] - The new accounting standards will be implemented starting in 2025, which may impact future financial reporting[23]

Core Viewpoint - He Yuan Bio's recombinant human albumin, derived from genetically modified rice, is positioned to challenge both domestic and international blood product giants, despite the company currently being unprofitable and facing significant market competition [2][3][7]. Group 1: Company Overview - He Yuan Bio (688765.SH) has recently listed on the Sci-Tech Innovation Board after a two-year suspension, marking the restart of the "fifth set" rules [3]. - The company has incurred losses of 480 million yuan over the past three years, with its success hinging on the profitability of its rice-derived blood products [3]. - The IPO price was set at 29.06 yuan per share, aiming to raise approximately 2.6 billion yuan, with 1.657 billion yuan allocated for the establishment of a recombinant human albumin industrialization base [4]. Group 2: Product Details - The core product is "rice blood," a plant-based recombinant human albumin, which is currently the only commercialized product of He Yuan Bio [3]. - The product is priced at 890 yuan for a 10g (20%, 50mL) bottle, which is more than double the price of human blood albumin available in the market [3][15]. - The market for human serum albumin in China was valued at 25.8 billion yuan in 2020, with projections to reach 57 billion yuan by 2030 [10]. Group 3: Market Position and Competition - He Yuan Bio aims to capture nearly 20% of the domestic market for human albumin, which is currently dominated by imported products [5][11]. - The company’s product is positioned as a safer alternative to human-derived albumin, eliminating risks associated with bloodborne pathogens [14]. - Despite the claimed cost advantages, the current pricing strategy suggests that He Yuan Bio's product is more expensive than traditional human blood albumin [15][16]. Group 4: Future Prospects - He Yuan Bio plans to expand its market presence, with a focus on entering the U.S. market and completing clinical trials for additional indications [12]. - The company has established a production line with an annual capacity of 10 tons and plans to expand to 120 million tons by 2026 [10]. - The company is also developing other products using the same technology, including recombinant human lactoferrin and α-1 antitrypsin [19].

Core Viewpoint - He Yuan Bio, an unprofitable innovative pharmaceutical company, has listed on the Sci-Tech Innovation Board, aiming to challenge domestic and international blood product giants with its unique plant-based recombinant human albumin derived from rice [1][2]. Group 1: Company Overview - He Yuan Bio's core product is "rice-derived blood," specifically the world's first plant-based recombinant human albumin, which is currently its only commercialized product [1]. - The company has incurred losses of 480 million yuan over the past three years, and its ability to achieve profitability hinges on the success of its rice-derived albumin [1]. - The IPO price was set at 29.06 yuan per share, with plans to raise approximately 2.6 billion yuan, of which 1.657 billion yuan is allocated for building an industrialization base for recombinant human albumin [1]. Group 2: Market Position and Competition - He Yuan Bio aims to capture nearly 20% of the domestic human albumin market, which is valued at 258 billion yuan in 2020 and projected to reach 570 billion yuan by 2030 [3][4]. - The company has established a commercial production line with an annual capacity of 10 tons and plans to expand to 120 tons by 2026 [3]. - The current market for human albumin in China is heavily reliant on imports, with imported products accounting for 66% of the market as of mid-2025 [3][4]. Group 3: Product Pricing and Cost Structure - He Yuan Bio's recombinant human albumin is priced at 890 yuan per 10g (20%, 50mL) bottle, which is more than double the price of human-derived albumin, typically priced between 350-400 yuan [2][6]. - The company claims that its plant-based albumin production will eventually lower costs compared to plasma-derived products, with a projected price of around 38 yuan/g once it enters the market [7]. - The company is actively seeking to have its product included in the medical insurance directory to enhance market access and affordability [7]. Group 4: Clinical Development and Future Plans - Currently, He Yuan Bio's recombinant human albumin has only one approved indication for treating liver cirrhosis with low albumin levels, which represents about 30% of the overall market [4][5]. - The company is focused on expanding its clinical trials in the U.S., with plans to complete Phase III trials by 2025 and submit for market approval in 2026 [5]. - Other products in development include recombinant human lactoferrin and recombinant human α-1 antitrypsin, with ongoing clinical trials for various indications [8].

Core Viewpoint - He Yuan Bio, an unprofitable innovative pharmaceutical company, has listed on the Sci-Tech Innovation Board, challenging domestic and international blood product giants with its unique plant-based recombinant human albumin derived from rice [2][3]. Company Overview - He Yuan Bio's core product is "rice-derived blood," specifically the world's first plant-based recombinant human albumin, which is currently its only commercialized product. The company has incurred losses of 480 million yuan over the past three years [2]. - The IPO price was set at 29.06 yuan per share, aiming to raise approximately 2.6 billion yuan, with 1.657 billion yuan allocated for the construction of an industrialization base for recombinant human albumin [2]. Market Potential - The recombinant human albumin market in China was valued at 25.8 billion yuan in 2020, with projections of reaching 57 billion yuan by 2030. He Yuan Bio aims to capture nearly 20% of the domestic market [4]. - The company has established a commercial production line with an annual capacity of 10 tons and plans to expand to 120 tons by 2026 [4]. Competitive Landscape - He Yuan Bio's plant-based recombinant human albumin directly competes with human-derived blood products and aims to address the limited domestic blood plasma supply, which has led to a reliance on imports [3][4]. - The company claims that its product is safer due to the absence of blood plasma donation and has comparable efficacy to human-derived albumin [6]. Pricing Strategy - The current market price for He Yuan Bio's recombinant human albumin is 890 yuan per 10g, significantly higher than the 350-400 yuan range for human-derived products [6][9]. - The company anticipates that production costs will decrease with scale, and it plans to apply for inclusion in the medical insurance directory to potentially lower prices further [9]. Product Development - He Yuan Bio is currently focused on the clinical trial for its recombinant human albumin, with plans to complete Phase III trials in the U.S. by 2025 and submit for market approval in 2026 [5]. - Other products in development include recombinant human lactoferrin and recombinant human α-1 antitrypsin, with ongoing clinical trials for various indications [10].